Abstract: The invention concerns the use of pyridinium furosemide or one of the derivatives, analogs, salts, metabolites, or prodrugs thereof in the preparation of a chemical model of a neurodegenerative disease, preferably Parkinson's disease. The invention also concerns the corresponding chemical model and the uses of same, in particular in screening tests for identifying drug candidates.
Type:
Grant
Filed:
November 19, 2013
Date of Patent:
August 29, 2017
Assignees:
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE PARIS-EST CRETEIL VAL DE MARNE
Abstract: The present invention relates methods and compositions for preventing or treating various immune diseases including graft-versus-host disease (GVHD) using populations or compositions of immunoregulatory T cells specific for an irrelevant antigen; such cells being activated in vivo by a simultaneous, separate or sequential administration of said antigen.
Type:
Application
Filed:
February 7, 2017
Publication date:
August 3, 2017
Applicants:
Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Paris Diderot Paris 7, Universite Paris Est Creteil Val De Marne
Inventors:
José Cohen, Gaelle Martin, Sébastein Maury, Benoit Salomon
Abstract: The present invention relates to hybrid fumarate-CO-releasing molecules capable of increasing heme oxygenase-1 (HO-1) activity and HO-1 protein expression and simultaneously releasing CO, their synthesis and their use in therapeutic applications, in particular their use in the treatment of inflammatory or cardiovascular diseases.
Type:
Application
Filed:
March 20, 2015
Publication date:
June 22, 2017
Applicants:
UNIVERSITE PARIS EST CRETEIL VAL DE MARNE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Inventors:
Roberto MOTTERLINI, Roberta FORESTI, Thierry MARTENS, Michael RIVARD
Abstract: The present invention relates to methods and pharmaceutical compositions for cardioprotection of subjects who experienced a myocardial infarction. In particular, the present invention relates to a ligand of the sonic hedgehog signaling pathway for use in the cardioprotection of a subject who experienced a myocardial infarction.
Type:
Grant
Filed:
January 14, 2014
Date of Patent:
November 29, 2016
Assignees:
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE MONTPELLIER, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, UNIVERSITE PARIS EST CRETEIL VAL DE MARNE
Inventors:
Alain Lacampagne, Jerome Thireau, Olivier Cazorla, Jean-Yves Le Guennec, Jeremy Fauconnier, Maria del Carmen Martinez, Ramaroson Andriantsitohaina, Bijan Ghaleh-Marzban, Raffaella Soleti
Abstract: The invention relates to a method for diagnosing, staging and/or monitoring a hemoglobin-related disorder such as ?-thalassemia or a treatment against said hemoglobin-related disorder in a subject in need thereof based on the detection and/or quantification the presence of free ?-Hb pool in a biological sample obtained from said subject.
Type:
Grant
Filed:
June 24, 2015
Date of Patent:
November 15, 2016
Assignees:
Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris-Sud, Assistance Publique—Hopitaux de Paris, Universite Paris Est Creteil Val de Marne
Abstract: The present invention relates to a method and compositions for the treatment of cystic fibrosis.
Type:
Grant
Filed:
August 13, 2013
Date of Patent:
August 2, 2016
Assignees:
INSERM (Institut National de la Sante et de la Recherche Medicale), Universite Paris-Est Creteil Val de Marne, Assistance Publique-Hopitaux de Paris
Abstract: The present invention relates to a ligand molecule that specifically binds to KTR3DL2 at the surface of KTR3DL2 expressing malignant T-cells for the treatment of lymphomas. It also relates to the in vitro use of a level of expression of KIR3DL2 is a biomarker useful for diagnosing and/or monitoring a lymphoma.
Type:
Application
Filed:
May 28, 2014
Publication date:
May 12, 2016
Applicants:
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, UNIVERSITE PARIS-EST CRETEIL VAL DE MARNE, UNIVERSITE PARIS DIDEROT - PARIS 7
Inventors:
Philippe GAULARD, Nicolas ORTONNE, Anne MARIE-CARDINE, Armand BENSUSSAN
Abstract: The present invention concerns new methods for treating cancer by using TYRO3 inhibitors and methods for identifying new molecules of interest for treating cancer.
Type:
Grant
Filed:
September 18, 2009
Date of Patent:
January 12, 2016
Assignees:
INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, UNIVERSITE PARIS-EST CRETEIL VAL DE MARNE
Inventors:
Isabelle Bernard-Pierrot, Francois Radvanyi, Yves Allory, Nicolas Stransky
Abstract: The invention relates to a method for diagnosing, staging and/or monitoring a hemoglobin-related disorder such as ?-thalassemia or a treatment against said hemoglobin-related disorder in a subject in need thereof based on the detection and/or quantification the presence of free ?-Hb pool in a biological sample obtained from said subject.
Type:
Application
Filed:
June 24, 2015
Publication date:
October 15, 2015
Applicants:
Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Paris-Sud, Assistance Publique - Hopitaux de Paris, Universite Paris Est Creteil Val de Marne
Abstract: A method for diagnosing and/or staging a hemoglobin disorder such as ?-thalassemia involves contacting a blood sample of a subject with an Alpha-Hemoglobin Stabilizing Protein which may be present on a solid support, and detecting and/or quantifying free ?-Hb. Detection or quantification can be achieved by photometry such as HTRF or immunological procedures such as EIA and ELISA. The free ?-Hb is compared to a reference value, and can be used to correlate with the diagnosis and/or staging of the hemoglobin disorder for the subject.
Type:
Grant
Filed:
April 23, 2010
Date of Patent:
August 4, 2015
Assignees:
Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Paris-Sud, Assistance Publique-Hopitaux de Paris, Universite Paris Est Creteil Val de Marne
Abstract: The invention relates to a synthetic gene coding for the Gag protein of the human immunodeficiency virus HIV-1. Said gene may optionally be fused with one or more other HIV sequences. The invention may notably be used within the scope of obtaining anti-HIV vaccines.
Type:
Grant
Filed:
September 10, 2009
Date of Patent:
January 13, 2015
Assignees:
Institut National de la Sante et de la Recherche Medicale, Centre National de la Recherche Scientifique, Universite Paris Est Creteil Val de Marne
Abstract: The present invention relates to a compound of formula (I): wherein: n is 0, 1 or 2; A is in particular CH or N; X is in particular CO, SO2, CS, and R1 is in particular H, R2 is a group of formula NR3R4 or OR5, R3 and R4 being in particular H, and R5 an alkyl group, R6 is in particular H or an alkyl group, and R7 is in particular an aryl group, for its use in the prevention and/or the treatment of viral pathologies or infections.
Type:
Grant
Filed:
February 21, 2014
Date of Patent:
December 2, 2014
Assignees:
Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Montpellier 1, Universite Paris-EST Creteil val de Marne, Assistance Publique-Hopitaux de Paris, Centre National de la Recherche Scientifique
Inventors:
Jean-Francois Guichou, Lionel Colliandre, Hakim Ahmed-Belkacem, Jean-Michel Pawlotsky
Abstract: The present invention provides a method for determining the RES phenotype in a tumor. The present invention further provides a method for predicting the sensitivity of a tumor to an epigenetic treatment, the method comprising determining the RES phenotype in said tumor, the presence of the RES phenotype in a tumor being indicative of a tumor sensitive to an epigenetic therapy. The present invention also provides a method for diagnosing an aggressive tumor and for selecting a patient affected with a tumor for an epigenetic therapy.
Type:
Application
Filed:
August 9, 2010
Publication date:
November 8, 2012
Applicants:
INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, UNIVERSITE PARIS-EST CRETEIL VAL DE MARNE, UNIVERSITE PARIS-SUD 11
Inventors:
Céline Vallot, Francois Radvanyi, Nicolas Stransky, Yves Allory
Abstract: The invention relates to the use of peptides corresponding to dermaseptin B2 or fragments thereof for treating proliferative diseases such as cancer or ocular lesions, and to pharmaceutical compositions containing such peptides.
Type:
Application
Filed:
June 29, 2010
Publication date:
July 19, 2012
Applicants:
UNIVERSITÉ PARIS EST CRETEIL VAL DE MARNE, UNIVERSITÉ PIERRE ET MARIE CURIE (PARIS 6)
Inventors:
Jean Delbe, Mohamed Amiche, Ali Ladram, Cécile Galanth, Pierre Nicolas, Yamina Hamma, Johanna Allegonda Anna Van Zoggel, José Courty
Abstract: The present invention concerns new methods for treating cancer by using TYRO3 inhibitors and methods for identifying new molecules of interest for treating cancer.
Type:
Application
Filed:
September 18, 2009
Publication date:
February 9, 2012
Applicants:
INSTITUT CURIE, UNIVERSITE PARIS-EST CRETEIL VAL DE MARNE, ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Inventors:
Isabelle Bernard-Pierrot, Francois Radvanyi, Yves Allory, Nicolas Stransky